Loading organizations...

FundamentalVR is a technology company.
FundamentalVR has raised $27.6M across 3 funding rounds.
FundamentalVR has raised $27.6M in total across 3 funding rounds.
FundamentalXR creates immersive solutions for knowledge acquisition and skills development in the medical sector, utilizing technologies like VR, AR, and AI.
FundamentalVR (now operating as Fundamental XR) is a healthcare technology company specializing in immersive surgical training platforms that integrate virtual reality (VR), haptics, machine learning, and data analytics to accelerate surgical skills development and improve patient outcomes.[1][2][7] Its core product, Fundamental Surgery, provides hardware-agnostic, customizable simulations for procedures across specialties like ophthalmology, urology, orthopedics, robotics, and endovascular interventions, serving medical device companies, pharmaceutical firms, hospitals, and educators.[1][2][4] The platform solves the competency gap in surgical training by enabling safe, repeatable rehearsals with realistic tactile feedback via patented HapticVR technology, mimicking tissue textures, tool resistance, and procedural sensations, while delivering measurable performance metrics.[1][3][4] Deployed in over 30 countries, it has raised $37.04M since its founding and continues to expand with multi-user collaboration and @HomeVR for remote access.[2][4][5]
FundamentalVR was co-founded by Richard Vincent, its CEO, around 2012-2015, with early offices in London and the US, evolving from a small team of three into a global operation.[3][5][2] The pivotal "Eureka" moment came during a knee surgery simulation demo, where Vincent realized haptic feedback allowed users to "truly touch a patient and genuinely interact" in VR, replicating real surgical feel—sparking the company's focus on immersive training.[3] This idea emerged from addressing surgical skill gaps exacerbated by global events like the health crisis, enabling remote, low-cost practice without physical patients.[3] Early traction built through partnerships with key opinion leaders (KOLs) and firms like Teleflex and CMR Surgical, refining simulations for precision, while the 2025 rebrand to Fundamental XR marked a decade of innovation in spatial tech.[1][6]
FundamentalVR rides the digital surgery wave, blending VR/AR haptics with AI to bridge training gaps in intelligent ORs amid surgeon shortages and rising minimally invasive procedures.[1][8] Timing aligns with post-pandemic remote learning demands and medtech innovation cycles, where simulations cut costs, speed regulatory evidence, and enable global skill-sharing without travel.[3][4] Market forces like haptic tech maturation and standalone VR hardware favor its hardware-agnostic model, influencing ecosystems by partnering with leaders (e.g., CMR Surgical's Versius) to standardize immersive training, lower adoption barriers, and provide data-driven insights for R&D.[1][2][6] Competitors like ORamaVR or ImmersiveTouch focus on narrower AR/VR planning, but FundamentalVR's haptic depth and multi-discipline scalability positions it as a leader in haptic-immersive medtech.[5]
Fundamental XR is poised to dominate haptic-immersive training as medtech shifts to robotics and personalized procedures, with expansions into AR/MR/web for broader accessibility and AI-enhanced analytics for predictive skill assessment.[6][7] Trends like spatial computing ubiquity and regulatory pushes for simulation-validated proficiency will amplify its impact, potentially doubling deployments via pharma salesforce tools and @HomeVR scalability. Its evolution from VR pioneer to full-spectrum immersive platform ties back to that knee surgery epiphany—proving tactile realism can redefine human capability in medicine.[3][6]
FundamentalVR has raised $27.6M in total across 3 funding rounds.
FundamentalVR's investors include Downing Ventures, Drew Burdon, EQT Life Sciences, Brighteye Ventures, Epic Private Equity, Mayo Clinic, Sana Kliniken, Albert E Sisto.
FundamentalVR has raised $27.6M across 3 funding rounds. Most recently, it raised $20.0M Series B in August 2022.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Aug 1, 2022 | $20.0M Series B | Downing Ventures, Drew Burdon | EQT Life Sciences |
| Oct 30, 2019 | $6.2M Other Equity / Series A | Downing Ventures | Brighteye Ventures, Epic Private Equity, Mayo Clinic, Sana Kliniken, Albert E Sisto |
| Oct 30, 2018 | $1.4M Other Equity | Albert E Sisto |